|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, STEMI (OR 1.61; CI 1.52-1.71), performed PCI (OR 2.65; CI 2.42-2.90) and Killip class >2 (OR 1.58; CI 1.36-1.84) favoured referral for CR, while age > 65 years, previous myocardial infarction, cerebrovascular disease or peripheral artery disease had a negative impact on referral for CR.
|
29657032 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined LVEDP/LVEF assessment was useful in predicting MACE after successful PCI for STEMI patients and could facilitate risk stratification, as it predicts LV remodeling.
|
29143103 |
2018 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this single-center prospective randomized study, patients with subacute STEMI presenting ≥12 and ≤48 h after symptom onset were randomized to primary PCI with or without manual TA in a 1:1 ratio.
|
29869443 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
The objective of the current study was to assess the prognostic value of ACEF scores in acute ST-segment elevation myocardial infarction (STEMI) patients with non-IRA CTO after successful primary PCI.
|
28940388 |
2018 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We chose the acute ST-elevation myocardial infarction (ASTEMI) patients treated with direct PCI to compare different administration routes of diltiazem.
|
30223281 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
There is some surrogate outcome data supporting deferring PCI in STEMI No hard data to support deferring PCI in STEMI No hard data to refute deferring PCI in STEMI Current national quality measures do not offer a method to adequately document appropriateness of deferring PCI.
|
29405597 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall no difference in ventricular rhythm disturbance was seen with intra-coronary nitrite treatment during primary PCI in STEMI patients, however nitrite treatment was associated with an important reduction in the incidence and severity of NSVT.
|
29887423 |
2018 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This paper presents a constructive critical appraisal of 7 key studies: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab), VEST (Vest Prevention of Early Sudden Death Trial), SECURE-PCI (Statins Evaluation in Coronary Procedures and Revascularization), TREAT (Ticagrelor in Patients with ST-Elevation Myocardial Infarction treated with Pharmacological Thrombolysis), POISE (PeriOperative ISchemic Evaluation), SMART-DATE (Safety of 6-Month Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome), and CVD-REAL 2 (Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors).
|
29753563 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consecutive patients from the Melbourne Interventional Group registry (2005-2014) who presented with STEMI and underwent primary PCI were included.
|
28963757 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
All patients presenting to the Alfred Hospital, a tertiary referral hospital, between 1 January 2010 and 31 December 2015 undergoing PCI for STEMI were identified.
|
28797607 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
We consecutively enrolled: a) 40 patients undergoing PCI of a chronic coronary total occlusion (CTO); b) 26 patients with ST-elevation myocardial infarction (STEMI) undergoing primary PCI (pPCI) of the infarct-related artery (IRA); c) 12 control patients undergoing angiography without significant coronary artery disease (CTRL).
|
29602581 |
2018 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We analysed the proportion of patients with ST-elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention within 90 minutes (primary PCI), the proportion of patients with hip fracture (HF) who underwent surgery within 2 days, and the proportion of women with primary C-section.
|
29584783 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) demonstrated superiority of routine early coronary angiography (and percutaneous coronary intervention [PCI]) compared with standard therapy in fibrinolytic-treated patients with ST-segment elevation myocardial infarction (STEMI) at 30 days.
|
29801739 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Reloaded patients were younger, had fewer comorbid conditions, and were more likely to be treated with primary PCI (STEMI) or an early invasive strategy (NSTEMI).
|
28541452 |
2018 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we compared the outcome of conscious survivors of OHCA presenting with ST-elevation myocardial infarction (STEMI) in post-resuscitation electrocardiogram undergoing immediate invasive coronary strategy with randomly selected STEMI patients without preceding OHCA undergoing primary PCI.
|
30244190 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Daily rIC starting on day 3 and continued for 4 weeks following successful P-PCI for STEMI did not improve LVEF as assessed by CMR after 4 months when compared with a matched control group.
|
29748420 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
The medical records of 998 patients who were diagnosed as STEMI and underwent emergency coronary angiography were retrospectively studied, SR was defined as achievement of TIMI grade 3 flow in the IRA before PCI.
|
29940881 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
This new score, which can be calculated in STEMI patients before PCI and used to predict no-reflow in STEMI patients, may help physicians to estimate the development of no-reflow in the pre-PCI period.
|
29193382 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
EMR on admission was independently correlated with 1-month and long-term all-cause mortality in STEMI patients undergoing P-PCI, suggesting EMR as a potential simple, useful, and inexpensive index for risk stratification of STEMI patients.
|
30416794 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Association between Monocyte HDL-C Ratio and SYNTAX Score and SYNTAX Score II in STEMI Patients Treated with Primary PCI.
|
29375221 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Impact of diagnostic ECG-to-wire delay in STEMI patients treated with primary PCI: a DANAMI-3 substudy.
|
29278352 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Use of the CADILLIAC Risk Score can accurately identify patients for safe early discharge after PCI for STEMI.
|
28612413 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
All patients in group 1 underwent elective angioplasty and stenting, whereas all patients included in groups 2 and 3 suffered from acute coronary syndromes (STEMI or NSTEMI) and underwent urgent PCI.
|
28425039 |
2017 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Door-to-balloon (DTB) time ≤90 min is an important quality indicator in the management of ST-elevation myocardial infarction (STEMI), but a considerable number of patients still do not meet this goal, particularly in countries outside the USA and Europe.Methods and Results:We analyzed 2,428 STEMI patients who underwent primary PCI ≤12 h of symptom onset who were registered in an ongoing prospective multicenter database (JCD-KiCS registry), between 2008 and 2013.
|
28228609 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite primary PCI being the well-established therapy, there are rooms for further research to optimize STEMI outcomes.
|
27846459 |
2017 |